Apogee Therapeutics Inc (NASDAQ: APGE) on Tuesday, soared 0.40% from the previous trading day, before settling in for the closing price of $39.58. Within the past 52 weeks, APGE’s price has moved between $26.20 and $63.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -34.37%. With a float of $36.22 million, this company’s outstanding shares have now reached $46.04 million.
Let’s look at the performance matrix of the company that is accounted for 196 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Apogee Therapeutics Inc (APGE) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Apogee Therapeutics Inc is 37.94%, while institutional ownership is 83.81%. The most recent insider transaction that took place on May 07 ’25, was worth 97,419. In this transaction Chief Medical Officer of this company sold 2,725 shares at a rate of $35.75, taking the stock ownership to the 244,448 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Medical Officer sold 3,860 for $36.22, making the entire transaction worth $139,801. This insider now owns 247,173 shares in total.
Apogee Therapeutics Inc (APGE) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -34.37% per share during the next fiscal year.
Apogee Therapeutics Inc (NASDAQ: APGE) Trading Performance Indicators
Apogee Therapeutics Inc (APGE) is currently performing well based on its current performance indicators. A quick ratio of 15.82 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.54, a number that is poised to hit -1.12 in the next quarter and is forecasted to reach -5.53 in one year’s time.
Technical Analysis of Apogee Therapeutics Inc (APGE)
Apogee Therapeutics Inc (NASDAQ: APGE) saw its 5-day average volume 0.66 million, a positive change from its year-to-date volume of 0.65 million. As of the previous 9 days, the stock’s Stochastic %D was 67.34%. Additionally, its Average True Range was 2.64.
During the past 100 days, Apogee Therapeutics Inc’s (APGE) raw stochastic average was set at 55.58%, which indicates a significant decrease from 80.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.67% in the past 14 days, which was lower than the 73.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.58, while its 200-day Moving Average is $44.53. Nevertheless, the first resistance level for the watch stands at $40.58 in the near term. At $41.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $42.79. If the price goes on to break the first support level at $38.36, it is likely to go to the next support level at $36.99. Assuming the price breaks the second support level, the third support level stands at $36.15.
Apogee Therapeutics Inc (NASDAQ: APGE) Key Stats
Market capitalization of the company is 2.37 billion based on 44,882K outstanding shares. Right now, sales total 0 K and income totals -182,150 K. The company made 0 K in profit during its latest quarter, and -67,220 K in sales during its previous quarter.
